Extended -
release guanfacine hydrochloride in 6 -17-year olds with ADHD: a randomised - withdrawal maintenance of efficacy study.
A controlled trial of extended -
release guanfacine and psychostimulants for attention - deficit / hyperactivity disorder.
Not exact matches
The other,
guanfacine, is currently used to treat high blood pressure and is thought to keep sensory neurons from
releasing glutamate into the spinal cord.
Last June the FDA also issued an «approvable letter» to Shire for another of its pending anti-ADHD products, Intuniv (
guanfacine), a once - a-day extended -
release tablet.